METHOD OF TREATING MODERATELY ACTIVE AND REPLICATIVE CHRONIC VIRAL HEPATITIS TYPE C OF 1-GENOTYPE Russian patent published in 2010 - IPC A61K31/4196 A61K31/711 A61K38/21 A61P1/16 A61P31/14 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to hepatology, and can be used in treating moderately active and replicative chronic viral hepatitis type C of 1-genotype. That is ensured by parenteral introduction of interferon-α in dosage 3 million IU and interferon-γ in dosage 500 thousand IU every second day and daily double oral introduction of Ribamidyl in dosage 15 mg per kg of body weight. Every 3 months, the interferon therapy is recessed for 10-12 days. Over this period, the preparation Derinat is administered daily. The total therapeutic course is 9 months and 20-24 days, and combined introduction of interferon-γ and interferon-α are performed within the first 6 months. For the next 3 months, interferon-a is administered. Ribamidyl is required for the whole therapeutic course.

EFFECT: higher clinical effectiveness and prevention of interferon-resistance development.

2 tbl, 4 ex